基于腮腺与颌下腺CT/MR影像组学预测头颈癌急性放射性口干
本研究回顾性分析266例头颈癌放疗患者,提取基线CT与T1增强MR上腮腺及颌下腺的影像组学特征,结合DVH参数建立预测放疗后3个月放射性口干的模型。内部队列(n=216)中联合临床、DVH、CT与MR特征的模型ROC-AUC为0.79±0.01,独立验证队列(n=50)为0.68。结果表明基线影像特征可能反映唾液腺功能与放疗损伤风险。
要点
- 基线CT与MR影像组学特征可能反映唾液腺功能及放射性损伤风险。
- 联合临床、DVH、CT与MR的模型在内部队列ROC-AUC达0.79±0.01。
- 独立验证队列中联合模型ROC-AUC为0.68,判别能力有限。
核心结论
- 基线CT与MR影像特征可能反映唾液腺基线功能及放射性损伤潜在风险。
- 将基线影像特征纳入预测模型有望改善口干风险分层,服务于个体化头颈癌放疗。
研究设计与样本
- 回顾性分析2009至2018年在本机构接受放疗的266例头颈癌患者。
- 前瞻性收集CT与T1增强MR图像及NCI-CTCAE 3个月随访口干分级。
- 图像配准后勾画腮腺与颌下腺,提取同侧与对侧腺体影像特征及DVH参数。
- 经Spearman相关预选(p<0.05)后行LASSO收缩回归,并以留一交叉验证评估变量选择内部效度。
- 采用重复十折交叉验证的广义线性回归建模,并在2017至2018年同机构50例独立数据集中验证。
主要发现
- 共筛选出7个CT特征、5个MR特征和2个DVH特征。
- 内部队列(n=216)中DVH、CT、MR及临床+DVH+CT+MR特征的ROC-AUC分别为0.73±0.01、0.69±0.01、0.70±0.01和0.79±0.01。
- 验证队列(n=50)中DVH、CT、MR及临床+DVH+CT+MR特征的ROC-AUC分别为0.63、0.57、0.66和0.68。
- DVH-ROC与CT-ROC(p=0.8)或MR-ROC(p=0.4)无显著差异;CT+MR-ROC与CT-ROC有显著差异(p=0.03),但与临床+DVH+CT+MR模型无显著差异(p=0.5)。
关键数值与推荐
- 口干结局采用NCI-CTCAE分级,评估时间为放疗后3个月。
- 特征预选标准为与口干相关的Spearman检验p<0.05。
- 内部队列(n=216)联合模型ROC-AUC为0.79±0.01,验证队列(n=50)为0.68。
临床怎么用
- 放疗前可基于CT与MR影像提取唾液腺特征,结合DVH与临床变量进行口干风险分层。
- 影像组学模型可作为DVH之外的补充信息,但独立验证判别能力有限,需谨慎用于个体化决策。
局限性
- 为单机构回顾性分析,外部泛化性需进一步验证。
- 独立验证队列样本量较小(n=50),模型判别能力低于内部队列。
- 原文未报告前瞻性干预或临床效用评估结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze baseline CT/MR-based image features of salivary glands to predict radiation-induced xerostomia 3-months after head-and-neck cancer (HNC) radiotherapy. METHODS: A retrospective analysis was performed on 266 HNC patients who were treated using radiotherapy at our institution between 2009 and 2018. CT and T1 post-contrast MR images along with NCI-CTCAE xerostomia grade (3-month follow-up) were prospectively collected at our institution. CT and MR images were registered on which parotid/submandibular glands were contoured. Image features were extracted for ipsilateral/contralateral parotid and submandibular glands relative to the location of the primary tumor. Dose-volume-histogram (DVH) parameters were also acquired. Features were pre-selected based on Spearman correlation before modelling by examining the correlation with xerostomia (p < 0.05). A shrinkage regression analysis of the pre-selected features was performed using LASSO. The internal validity of the variable selection was estimated by repeating the entire variable selection procedure using a leave-one-out-cross-validation. The most frequently selected variables were considered in the final model. A generalized linear regression with repeated ten-fold cross-validation was developed to predict radiation-induced xerostomia at 3-months after radiotherapy. This model was tested in an independent dataset (n = 50) of patients who were treated at the same institution in 2017-2018. We compared the prediction performances under eight conditions (DVH-only, CT-only, MR-only, CT + MR, DVH + CT, DVH + CT + MR, Clinical+CT + MR, and Clinical+DVH + CT + MR) using the area under the receiver operating characteristic curve (ROC-AUC). RESULTS: Among extracted features, 7 CT, 5 MR, and 2 DVH features were selected. The internal cohort (n = 216) ROC-AUC values for DVH, CT, MR, and Clinical+DVH + CT + MR features were 0.73 ± 0.01, 0.69 ± 0.01, 0.70 ± 0.01, and 0.79 ± 0.01, respectively. The validation cohort (n = 50) ROC-AUC values for DVH, CT, MR, and Clinical+DVH + CT + MR features were 0.63, 0.57, 0.66, and 0.68, respectively. The DVH-ROC was not significantly different than the CT-ROC (p = 0.8) or MR-ROC (p = 0.4). However, the CT + MR-ROC was significantly different than the CT-ROC (p = 0.03), but not the Clinical+DVH + CT + MR model (p = 0.5). CONCLUSION: Our results suggest that baseline CT and MR image features may reflect baseline salivary gland function and potential risk for radiation injury. The integration of baseline image features into prediction models has the potential to improve xerostomia risk stratification with the ultimate goal of truly personalized HNC radiotherapy.
引用
- Sheikh K, Lee SH, Cheng Z, et al. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands. Radiat Oncol. 2019. PMID: 31358029. doi:10.1186/s13014-019-1339-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。